|
FDA Approves Genentech’s Perjeta For HER2-Positive Breast Cancer
The FDA has approved Roche subsidiary Genentech’s Perjeta as part of a first-line treatment combination for patients with HER2-positive metastatic breast cancer.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives